I can sum up 's (NYSE: PFE) stock performance over the last couple of years in one word (and only three letters): ugh. Shares of the big drugmaker have plunged more than 50% since the high set in late 2022.

Pfizer's revenue and earnings are sinking like a brick. Big hurdles for the company lie ahead. All in all, this big pharma stock might look like one that investors won't want to touch with a 10-foot pole.

However, I'm actually bullish about Pfizer over the long term. Here's why it's a much better stock than you might think.

Continue reading

Source Fool.com